Am J Psychiatry 159:2055-2061, December 2002
© 2002 American Psychiatric Association
Outcomes of Prenatal Antidepressant Exposure
Gregory E. Simon, M.D., M.P.H.,
Michael L. Cunningham, M.D., Ph.D., and
Robert L. Davis, M.D., M.P.H.
OBJECTIVE: This study evaluated the effects of prenatal antidepressant exposure on perinatal outcomes, congenital malformations, and early growth and development. METHOD: Within a group-model health maintenance organization, all infants with apparent prenatal exposure to tricyclic or selective serotonin reuptake inhibitor (SSRI) antidepressants were frequency matched to an unexposed comparison group by year of birth, maternal age, and mother’s lifetime use of antidepressant drugs and mental health care. A structured blind review of mothers’ and infants’ medical records examined perinatal outcomes, congenital malformations, and developmental delay. RESULTS: Tricyclic antidepressant exposure was not associated with any significant difference in perinatal outcomes. Exposure to SSRIs was associated with a 0.9-week decrease in mean gestational age, a 175-g decrease in mean birth weight, and a 0.29 decrease in mean Apgar score at 5 minutes, but differences in birth weights and Apgar scores were not significant after adjustment for gestational age. Differences in gestational age and birth weights were unrelated to length of exposure, but differences in Apgar scores were limited to those with third-trimester exposure. Neither tricyclic antidepressant nor SSRI exposure was significantly associated with congenital malformations or developmental delay. CONCLUSIONS: The authors found no association between tricyclic antidepressant or SSRI exposure and either congenital malformations or developmental delay. SSRI exposure during pregnancy was associated with earlier delivery and consequent lower birth weight. Third-trimester SSRI exposure was also associated with lower Apgar scores. Women considering taking SSRIs during pregnancy may balance any higher fetal risk against the risk of persistent or recurrent depression.
This article has been cited by other articles:
|
|
|
|
 
J. W. Rich-Edwards, A. P. Mohllajee, K. Kleinman, M. R. Hacker, J. Majzoub, R. J. Wright, and M. W. Gillman
Elevated Midpregnancy Corticotropin-Releasing Hormone Is Associated with Prenatal, But Not Postpartum, Maternal Depression
J. Clin. Endocrinol. Metab.,
May 1, 2008;
93(5):
1946 - 1951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman
Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study
The British Journal of Psychiatry,
May 1, 2008;
192(5):
338 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suri, L. Altshuler, G. Hellemann, V. K. Burt, A. Aquino, and J. Mintz
Effects of Antenatal Depression and Antidepressant Treatment on Gestational Age at Birth and Risk of Preterm Birth
Am J Psychiatry,
August 1, 2007;
164(8):
1206 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Louik, A. E. Lin, M. M. Werler, S. Hernandez-Diaz, and A. A. Mitchell
First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects
N. Engl. J. Med.,
June 28, 2007;
356(26):
2675 - 2683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Alwan, J. Reefhuis, S. A. Rasmussen, R. S. Olney, J. M. Friedman, and the National Birth Defects Prevention Study
Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
N. Engl. J. Med.,
June 28, 2007;
356(26):
2684 - 2692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Donnelly and C. Paton
Safety of selective serotonin reuptake inhibitors in pregnancy
Psychiatr. Bull.,
May 1, 2007;
31(5):
183 - 186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Looper
Potential Medical and Surgical Complications of Serotonergic Antidepressant Medications
Psychosomatics,
February 1, 2007;
48(1):
1 - 9.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Oberlander, P. Reebye, S. Misri, M. Papsdorf, J. Kim, and R. E. Grunau
Externalizing and Attentional Behaviors in Children of Depressed Mothers Treated With a Selective Serotonin Reuptake Inhibitor Antidepressant During Pregnancy
Arch Pediatr Adolesc Med,
January 1, 2007;
161(1):
22 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ferreira, A. M. Carceller, C. Agogue, B. Z. Martin, M. St-Andre, D. Francoeur, and A. Berard
Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
Pediatrics,
January 1, 2007;
119(1):
52 - 59.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman
Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.
Arch Gen Psychiatry,
August 1, 2006;
63(8):
898 - 906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Bodnar, K. R. Sunder, and K. L. Wisner
Treatment With Selective Serotonin Reuptake Inhibitors During Pregnancy: Deceleration of Weight Gain Because of Depression or Drug?
Am J Psychiatry,
June 1, 2006;
163(6):
986 - 991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Malm, T. Klaukka, and P. J. Neuvonen
Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy
Obstet. Gynecol.,
December 1, 2005;
106(6):
1289 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Mornson, D. W. Rurak, C. Chien, D. J. Kennaway, N. Gruber, I. C. McMillen, and K. W. Riggs
Maternal Fluoxetine Infusion Does Not Alter Fetal Endocrine and Biophysical Circadian Rhythms in Pregnant Sheep
Reproductive Sciences,
July 1, 2005;
12(5):
356 - 364.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. J. Warden, A. G. Robling, M. S. Sanders, M. M. Bliziotes, and C. H. Turner
Inhibition of the Serotonin (5-Hydroxytryptamine) Transporter Reduces Bone Accrual during Growth
Endocrinology,
February 1, 2005;
146(2):
685 - 693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Oberlander, R. E. Grunau, C. Fitzgerald, M. Papsdorf, D. Rurak, and W. Riggs
Pain Reactivity in 2-Month-Old Infants After Prenatal and Postnatal Selective Serotonin Reuptake Inhibitor Medication Exposure
Pediatrics,
February 1, 2005;
115(2):
411 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Fricchione
Generalized Anxiety Disorder
N. Engl. J. Med.,
August 12, 2004;
351(7):
675 - 682.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. SUNDER and K. L. WISNER
Antidepressants and Premature Labor
Am J Psychiatry,
May 1, 2004;
161(5):
925 - 926.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Andersson, I. Sundstrom-Poromaa, M. Wulff, M. Astrom, and M. Bixo
Neonatal Outcome following Maternal Antenatal Depression and Anxiety: A Population-based Study
Am. J. Epidemiol.,
May 1, 2004;
159(9):
872 - 881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Kallen
Neonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy
Arch Pediatr Adolesc Med,
April 1, 2004;
158(4):
312 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Zeskind and L. E. Stephens
Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior
Pediatrics,
February 1, 2004;
113(2):
368 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kohen
Psychotropic medication in pregnancy
Advan. Psychiatr. Treat.,
January 1, 2004;
10(1):
59 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rosack
Study Finds No Link Between Antidepressants, Birth Defects
Psychiatr News,
December 20, 2002;
37(24):
18 - 18.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
